Overview
Optimizing Antibiotic Therapy to Treat Gram-negative Pathogens and Improve Outcomes in HAP/VAP
HAP/VAP Case Study: Clinician Education
Click the"View Activity" button to view this activity.
View ActivityActivity already occured. CME/CE is no longer available for this activity
George Karam, MD reviews a HAP/VAP patient case presented along with a faculty panel at MAD-ID 2019. Discussion topics include challenges with P. aeruginosa, ensuring effectiveness of antibiotics while reducing resistance, as well as new and emerging approaches to Gram-negative organisms.
This activity is intended for ID specialists, hospitalists, pharmacists and other healthcare professionals who care for patients with serious infections.
The purpose of this activity is to provide clinicians who care for patients with serious infections with the latest data on antimicrobial stewardship, available and emerging antibiotics against Gram-negative pathogens, and the optimization of therapy to improve outcomes and reduce resistance.
Upon completion of this activity, participants will be able to:
• Summarize the burden of HAP/VAP and challenges associated with its management
• Outline patient and clinical factors that increase risks for resistant Gram-negative pathogens
• Describe strategies to optimize antimicrobial therapy to ensure effectiveness and reduce resistance
• Summarize the burden of HAP/VAP and challenges associated with its management
• Outline patient and clinical factors that increase risks for resistant Gram-negative pathogens
• Describe strategies to optimize antimicrobial therapy to ensure effectiveness and reduce resistance
Sponsored by the Academy for Continued Healthcare Learning (ACHL).
Supported by an educational grant from Merck & Company.
1. Active Internet connection (DSL or Cable). Dial-up connection will have constant buffering problem.
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
2. Compatible with Windows PC and MAC (256 MB of RAM or higher)
3. Activity is best viewed on Internet Explorer 9.0 or higher, Safari 5.0 or higher and Firefox 29.0 or higher
4. Adobe Flash Player 12.0 (or higher). Click here to download Adobe Flash Player for free.
5. Adobe Reader to print certificate. Click here to download Adobe Reader for free.
6. Allow ActiveX controls to run on your computer: If the yellow strip appears on the top of your web browser while running the Webcast, right click on it and select Allow blocked contents to run.
Turn the Pop-up blocker off: On the Tools menu, point to Pop-up Blocker, and then click Turn Off Pop-up Blocker
I. VAP/HAP: Case Presentation
II. Challenges with P. aeruginosa
III. Ensuring Effectiveness of Antibiotics and Reducing Resistance
IV. New and Emerging Approaches to Gram-negative Organisms
II. Challenges with P. aeruginosa
III. Ensuring Effectiveness of Antibiotics and Reducing Resistance
IV. New and Emerging Approaches to Gram-negative Organisms
George H. Karam, MD
Paula Garvey Manship Chair of Medicine
Head of the LSUHSC Dept. of Internal Medicine
Louisiana State University
Baton Rouge, LA
Paula Garvey Manship Chair of Medicine
Head of the LSUHSC Dept. of Internal Medicine
Louisiana State University
Baton Rouge, LA
James Lewis, II, PharmD, FIDSA
Infectious Disease Clinical Pharmacy Supervisor
Co-Director of Antibiotic Stewardship
Department of Pharmacy
Oregon Health & Science University
Portland, OR
Jason M. Pogue, PharmD, BCPS-ID
Clinical Pharmacist, Infectious Diseases
Sinai-Grace Hospital
Detroit Medical Center
Clinical Assistant Professor of Medicine
Wayne State University School of Medicine
Detroit, MI
Patricia (Trish) Simner, PhD, D(ABMM)
Director of Medical Bacteriology and Parasitology Laboratories
Associate Professor of Pathology
Johns Hopkins School of Medicine
Baltimore, MD
The Academy for Continued Healthcare Learning (ACHL) requires that the faculty participating in a CME/CE/CPE activity disclose all affiliations or other financial relationships (1) with the manufacturers of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation and (2) with any commercial supporters of the activity. All conflicts of interest have been resolved prior to this CME/CE/CPE activity.
The following financial relationships have been provided:
George H. Karam, MD
Advisory Board: Merck, Paratek, and Shionogi
Consultant: Shionogi and Tetraphase
Honoraria Recipient: Merck
James S. Lewis II, PharmD, FIDSA
Consultant: Merck and Tetraphase
Jason M. Pogue, PharmD
Consultant: Melinta, Merck, Nabriva, Shionogi, and Tetraphase
Speakers Bureau: Melinta and Merck
Grant Support: Merck
Patricia J. Simner, MSc, PhD:
Consultant: Accelerate Diagnostics, CosmosID, OpGen Inc., and Roche Diagnostics
Research Grants: Accelerate Diagnostics, Affinity Biosensors, Check-Points BV, Hardy Diagnostics, and OpGen Inc.
Discussion of Off-Label, Investigational, or Experimental Drug/Device Use: Novel antibiotics and available antibiotics under investigation for use in different types of serious infections.
ACHL staff members and others involved with the planning, development, and review of the content for this activity have no relevant affiliations or financial relationships to disclose.
The content for this activity was developed independently of the commercial supporter. All materials are included with permission. The opinions expressed are those of the faculty and are not to be construed as those of the publisher or grantor.
This educational activity was planned and produced in accordance with the ACCME Accreditation Criteria, Policies, and Standards for Commercial Support, as well as the ACPE Accreditation Standards for Continuing Pharmacy Education. Recommendations involving clinical medicine in a continuing medical education (CME/CE) activity must be based on evidence that is accepted within the profession of medicine as adequate justification for their indications and contraindications in the care of patients. All scientific research referred to, reported, or used in CME/CE in support or justification of a patient care recommendation must conform to the generally accepted standards of experimental design, data collection, and analysis.
This CME/CE activity might describe the off-label, investigational, or experimental use of medications and/or devices that may exceed their FDA-approved labeling. Physicians should consult the current manufacturers’ prescribing information for these products. ACHL requires the speaker to disclose that a product is not labeled for the use under discussion.
This activity will take approximately 30 minutes to complete. To receive credit, participants are required to view the online activity and complete the posttest and evaluation. To receive credit, 75% must be achieved on the posttest. A certificate will be immediately available. There is no fee to participate in the activity or for the generation of the certificate.
CPE credit will be submitted to CPE Monitor® on the first day of each month.
For questions, contact Katlyn Cooper at kcooper@achlcme.org
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
The Academy for Continued Healthcare Learning designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The Academy for Continued Healthcare Learning is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
This activity has been approved for 0.5 contact hours.
ACPE Universal Activity Number: 0396-0000-19-006-H01-P
Activity Type: Knowledge
The Academy for Continued Healthcare Learning (ACHL) has been accredited as an Authorized Provider by the International Association for Continuing Education and Training (IACET). In obtaining this accreditation, the ACHL has demonstrated that it complies with the ANSI/IACET Standard which is recognized internationally as a standard of good practice. As a result of the Authorized Provider status, ACHL is authorized to offer IACET CEUs for programs that qualify under the ANSI/IACET Standard.
ACHL is authorized by IACET to offer 0.1 CEU for this program.
IACET CEUs are accepted by the American Nurses Association. Contact your licensing agency for details.